EP-1229: Phase II trial of concurrent erlotinib in locally advanced non-small cell lung cancer (LA-NSCLC). (May 2017) - Hansen, O.; Knap, M.; Khalil, A.; Nyhus, C.; Brink, C.; Hoffmann, L.; Schytte, T.